Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

This publication has 25 references indexed in Scilit:

• Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
  BMC Endocrine Disorders, 2008
• Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
  Current Medical Research and Opinion, 2008
• Metformin therapy and clinical uses
  Diabetes & Vascular Disease Research, 2008
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
  Diabetes, Obesity and Metabolism, 2007
• Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
  Current Medical Research and Opinion, 2007
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial
  Diabetes, Obesity and Metabolism, 2007
• Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
  New England Journal of Medicine, 2006
• Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
  International Journal Of Clinical Practice, 2006
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
  The Lancet, 2006
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
  Diabetologia, 2006